Angiogenetic Factors and Biochemical Markers of Bone Metabolism in POEMS Syndrome Treated with High-Dose Therapy and Autologous Stem Cell Support
Authors:
- Efstathios KastritisEKEfstathios Kastritis
- Evangelos TerposETEvangelos Terpos
- Athanasios AnagnostopoulosAAAthanasios Anagnostopoulos
- Irini XilouriIXIrini Xilouri
- Meletios Athanasios DimopoulosMeletios Athanasios Dimopoulos
- 1 July 2006
- journal article
- case report
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 7 (1) , 73-76
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratioLeukemia, 2005
- Polyneuropathy in POEMS syndrome: role of angiogenic factors in the pathogenesisBrain, 2005
- Myeloma bone disease: pathophysiology and managementAnnals of Oncology, 2005
- Peripheral blood stem cell transplantation in 16 patients with POEMS syndrome, and a review of the literatureBlood, 2004
- Serum levels of macrophage inflammatory protein‐1 alpha (MIP‐1α) correlate with the extent of bone disease and survival in patients with multiple myelomaBritish Journal of Haematology, 2003
- POEMS syndrome: definitions and long-term outcomeBlood, 2003
- Highly concentrated vascular endothelial growth factor in platelets in Crow-Fukase syndromeMuscle & Nerve, 2000
- Overproduction of vascular endothelial growth factor/vascular permeability factor is causative in crow-fukase (POEMS) syndromeMuscle & Nerve, 1998
- Greatly raised vascular endothelial growth factor (VEGF) in POEMS syndromeThe Lancet, 1996
- Elevated levels of interleukin-1 beta (IL-1 beta) and IL-6 in serum and increased production of IL-1 beta mRNA in lymph nodes of patients with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes (POEMS) syndromeBlood, 1994